N Engl J Med; Volume 373(17): ; October 22, 2015

Slides:

Advertisements

Similar presentations

IDEAL 1 and IDEAL 2.

Advertisements

Maintenance therapy for NSCLC

James R. Rigas Comprehensive Thoracic Oncology Program

Using Non-targeted Therapies in Targeted Lung Cancer Populations Nathan Pennell, M.D., Ph.D. September 6, 2014.

PCODR Experience with Adaptive Clinical Trial Designs Tony Fields Chair pCODR Expert Review Committee CADTH.

Network Experience of TKI inhibitors as 1 st line use in advanced NSCLC Dr Jill Gardiner and Mr Steve Williamson April 2012.

Lung cancer perspectives. Targeted therapy : one for all or a few for one ? Miklos Pless, Winterthur

Treatment of advanced NSCLC:

A paradigm shift in the treatment of advanced lung cancer: survival and symptom benefits with Tarceva Tudor-Eliade Ciuleanu Cancer Institute Ion Chiricuta.

Overall survival in NSCLC

ESMO 2011 Lung Cancer Vantage 014 Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

R4 박재훈 / F 황인경. Introduction Squamous-cell carcinoma about 30% of NSCLC Treatment for advanced squamous-cell NSCLC docetaxel for secondline.

이근욱 분당서울대학교병원/서울의대 혈액종양내과 부교수

© MediPaper 2016 ASCO 2016 Atezolizumab Data MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after.

POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.

KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

ESMO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.

Julie Brahmer, M. D. , Karen L. Reckamp, M. D. , Paul Baas, M. D

Recent Advances in NSCLC Treatment

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

Wolfram C. M. Dempke SaWo Oncology Ltd May 13, 2017

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Metastatic Head Neck Cancer and Immunotherapy

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Rosell R et al. Proc ASCO 2011;Abstract 7503.

advanced lung adenocarcinoma subtype

Bladder Cancer: A New Era in Treatment

Improved Survival With Nivolumab vs Docetaxel in Pts With Advanced Squamous Cell NSCLC After Platinum-Containing Chemotherapy: CheckMate 017 Slideset on:

Caris Molecular Intelligence®

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.

Intervista a Lucio Crinò

Evolving Paradigms in Recurrent/Metastatic SCCHN

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

The Immune System. The Immune System Adaptive Immune Response.

Advanced NSCLC Without Actionable Mutations

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

Intervista a Cesare Gridelli

Immunotherapy Combinations for Lung Cancers

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing Klazien Matter-Walstra, PhD, Matthias.

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Basics of Immunotherapy Potential Therapeutic Targets.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Oncologia Polmonare – AOU S. Luigi Gonzaga, Orbassano (To)

Domenica 03 giugno Highlight a cura di Filippo de Marinis

during cancer immunotherapy

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Practical Guidance on the Management of Pan-Negative NSCLC

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Preparing for Checkpoint Inhibitors in Breast Cancer

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Third-Generation EGFR TKIs

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab;

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Updates in Best Practices in Non-Small Cell Lung Cancer

Uncovering the Right Sequence

Presentation transcript:

N Engl J Med; Volume 373(17):1627-1639; October 22, 2015 R3 이지훈 / Prof. 백선경

BACKGROUND 2nd line treatment for advanced NSCLC Docetaxel : anti-mitotics Pemetrexed (Alimta) : folate antimetabolites Erlotinib (Tarceva) : EGFR inhibitor

BACKGROUND Nivolumab a fully human IgG4 anti-PD-1 monoclonal Ab “Cancer Immunotherapy” Restore antitumor immunity In phase 1 studies Durable antitumor activity Encouraging results on survival in all NSCLC subtypes Response rate : 17.6% Overall survival : 42%(1yr) → 23%(2yrs) → 16%(3yrs) Progression-free survival : 18% at 1 year

BACKGROUND

METHODS

RESULTS

RESULTS

RESULTS

CONCLUSION Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel.